The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Orion Oyj's Revenue for the
three
months ended in Mar. 2026 was €418 Mil. Orion Oyj's average Accounts Receivable for the
three
months ended in Mar. 2026 was €451 Mil.
Hence, Orion Oyj's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.93.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Orion Oyj Receivables Turnover Related Terms
Orion Oyj Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Orion Oyj's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OFK vs LLY, JNJ, ABBV: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Orion Oyj's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Oyj (STU:OFK) has a Receivables Turnover of 0.93 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Orion Oyj and its competitors. According to the industry distribution chart, Orion Oyj ranks #401 out of 947 companies in the Drug Manufacturers industry, placing it in the top 42.3%.
Is Orion Oyj's Receivables Turnover too high?
Orion Oyj's current Receivables Turnover is 0.93. The Drug Manufacturers industry median Receivables Turnover is 5.07. Orion Oyj's value of 0.93 is 81.7% below this industry median. Based on the distribution chart, Orion Oyj ranks #401 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Oyj has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's Receivables Turnover compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #401 out of 947 companies for Receivables Turnover. This puts Orion Oyj in the upper half of its industry. The industry median Receivables Turnover is 5.07. Orion Oyj's value of 0.93 is 81.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current Receivables Turnover of 0.93 is 81.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current Receivables Turnover is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Based on GuruFocus' analysis, Orion Oyj (STU:OFK) is currently considered Fairly Valued. The stock's GF Value™ is €70.61, compared to a current price of €69.70 — trading 1.3% below its estimated fair value. The current Receivables Turnover is 0.93 and 81.7% below the Drug Manufacturers industry median of 5.07. Orion Oyj's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Orion Oyj (STU:OFK), the current Receivables Turnover is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (STU:OFK) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be undervalued.
The current stock price of €69.70 is trading 1.3% below its estimated GF Value™ of €70.61.
GuruFocus considers Orion Oyj to be Fairly Valued.
Key valuation signals for STU:OFK:
Receivables Turnover: 0.93
GF Value™: €70.61 vs. price of €69.70 (1.3% below fair value)
Industry Position: 81.7% below the Drug Manufacturers median (#401 of 947)
No single metric tells the full story. See the STU:OFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
86GF Score
Get the complete analysis for STU:OFK
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OFK has been successfully added to your 
